A number of exciting Licensing and Investment opportunities emerging from Ithaka's client portfolio are outlined below. If you wish to obtain further information on a particular opportunity please contact a member of the team, as shown at the foot of this page.

CrossGen
CrossGen is a recently formed company using proprietary comparative genome hybridisation microarray technology to provide a unique service to the pharmaceutical industry. CrossGen develops orthologous microarrays for species with less well-characterised genomes. CrossGen’s microarrays are particulaly useful for toxicology studies in early pre-clinical trials. They can also be used for the development of veterinary pharmaceuticals and the identification of surrogate markers
The Company seeks development partners and investment funding

De Montfort Biosciences.
De Montfort Bioscience (DMB) is a spin-out company from De Montfort University that is developing reagents and services to the pharmaceutical industry for the identification of potential toxicity of drug candidates. The company also plans to develop its own drug discovery expertise in the oncology field.
The Company seeks development partners and investment funding

Psynova Neurotech,
Psynova Neurotech is a UK based company developing and exploiting novel biomarkers for Neuropsychiatric illness. Ithaka was appointed by the Cambridge University Proof of Concept Fund to develop the business plan, following which Dr Paul Rodgers was appointed as Chairman of the new company. Ithaka has successfully supported the raising of a £2.25 million funding package from Porton Capital and Cambridge Enterprise Seed Funds.
The Company seeks development partners and investment funding

Theryte,
Theryte is developing novel anti-cancer drugs based on an understanding of the genes involved in maintaining the viability of cancer cells developed by the Theryte founding scientist, Prof Hilmar Warenius.
Theryte has negotiated and signed research contracts and collaboration deals with commercial operations in the UK and continental Europe, and with the Universities of Southampton and Bradford.
The Company seeks development partners and investment funding

Ziva Bioscience Ltd: A new reproductive healthcare biotechnology business is seeking partnerships or investment funding to develop the company’s novel immuno-contraceptive and also for its implantation promoter for use with In Vitro Fertilisation processes. The company is also seeking partners for exploitation of its technology in the animal health sector.

Creative Gene Technology Ltd: Exploiting new techniques in plant genomics and proteomics to develop strategic opportunities for the renewable energy (e.g. biodiesel), chemical feedstocks (e.g. oils and starches) and agriculture industries (e.g. novel herbicides and other pest control strategies). The company is seeking investment funding. Opportunities are available for licensing of proprietary tools and product candidates to third parties.

Ampika Ltd: Seeks partnerships and investment funding to develop nutraceuticals and phytomedicine products derived from a unique database of Amazonian medicinal plants.

For Information contact:

Paul Rodgers
Tel: +44 (0) 1223 703146
Email: paul.rodgers@ithaka.co.uk